A surrogate-based approach for post-genomic partner identification

<p>Abstract</p> <p>Background</p> <p>Modern drug discovery is concerned with identification and validation of novel protein targets from among the 30,000 genes or more postulated to be present in the human genome. While protein-protein interactions may be central to man...

Full description

Bibliographic Details
Main Authors: Giordano Tony, Eder Paul S, Brissette Renee, Hsiao Ku-chuan, Pillutla Renuka C, Fletcher Paul W, Lennick Michael, Blume Arthur J, Goldstein Neil I
Format: Article
Language:English
Published: BMC 2001-09-01
Series:BMC Biotechnology
Online Access:http://www.biomedcentral.com/1472-6750/1/6
Description
Summary:<p>Abstract</p> <p>Background</p> <p>Modern drug discovery is concerned with identification and validation of novel protein targets from among the 30,000 genes or more postulated to be present in the human genome. While protein-protein interactions may be central to many disease indications, it has been difficult to identify new chemical entities capable of regulating these interactions as either agonists or antagonists.</p> <p>Results</p> <p>In this paper, we show that peptide complements (or surrogates) derived from highly diverse random phage display libraries can be used for the identification of the expected natural biological partners for protein and non-protein targets. Our examples include surrogates isolated against both an extracellular secreted protein (TNFβ) and intracellular disease related mRNAs. In each case, surrogates binding to these targets were obtained and found to contain partner information embedded in their amino acid sequences. Furthermore, this information was able to identify the correct biological partners from large human genome databases by rapid and integrated computer based searches.</p> <p>Conclusions</p> <p>Modified versions of these surrogates should provide agents capable of modifying the activity of these targets and enable one to study their involvement in specific biological processes as a means of target validation for downstream drug discovery.</p>
ISSN:1472-6750